01 July 2016

A million for hemophilia gene therapy

The British investment fund UCL Technology Fund will invest 1 million pounds (1.3 million euros) in the biopharmaceutical company Freeline Therapeutics, according to the European Pharmaceutical Review (UCL Technology Fund invests 1m pounds in gene therapy company, Freeline).

Freeline develops and commercializes gene therapy for the treatment of blood diseases, in particular, hemophilia. The company was founded in December 2015 by the British Syncona Foundation and the UCL Business technology transfer company of University College London.

The main product in the development of Freeline is gene therapy based on adenoassociated virus. The drug has already successfully passed the first stage of clinical trials involving 10 patients suffering from type B hemophilia.

Portal "Eternal Youth" http://vechnayamolodost.ru 01.07.2016

Found a typo? Select it and press ctrl + enter Print version

gene therapy
hereditary diseases
investments

CRISPR with high load capacity

The new method allows the introduction of giant DNA fragments several thousand nucleotides long into genomes.
28 November 2022
A new record

The FDA has approved the first therapy against hemophilia B from UniQure. The drug will become the most expensive in the world with a price of $ 3.5 million.
24 November 2022
Watch out for mice

Most likely, the review of the article on the results obtained on mice will not undermine the credibility of Zolgensma, and it will continue to be prescribed to patients.
31 October 2022
Injection will save you from excess iron

Gene therapy led to the restoration of iron levels in mouse models of hemochromatosis.
26 October 2022
Cellular gene therapy

Experiments on an animal model have shown the possibility of treating Duchene's myodystrophy by delivering therapeutic genes in stem cells.
27 September 2016

A million for hemophilia gene therapy

Related posts

CRISPR with high load capacity

A new record

Watch out for mice

Injection will save you from excess iron

Cellular gene therapy